IL139591A0 - Combination therapy for treatment of bipolar disorders - Google Patents

Combination therapy for treatment of bipolar disorders

Info

Publication number
IL139591A0
IL139591A0 IL13959199A IL13959199A IL139591A0 IL 139591 A0 IL139591 A0 IL 139591A0 IL 13959199 A IL13959199 A IL 13959199A IL 13959199 A IL13959199 A IL 13959199A IL 139591 A0 IL139591 A0 IL 139591A0
Authority
IL
Israel
Prior art keywords
treatment
combination therapy
bipolar disorders
bipolar
disorders
Prior art date
Application number
IL13959199A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL139591A0 publication Critical patent/IL139591A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrotherapy Devices (AREA)
IL13959199A 1998-05-29 1999-05-21 Combination therapy for treatment of bipolar disorders IL139591A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8712698P 1998-05-29 1998-05-29
PCT/US1999/011314 WO1999062522A1 (fr) 1998-05-29 1999-05-21 Therapie combinee de traitement de troubles bipolaires

Publications (1)

Publication Number Publication Date
IL139591A0 true IL139591A0 (en) 2002-02-10

Family

ID=22203275

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13959199A IL139591A0 (en) 1998-05-29 1999-05-21 Combination therapy for treatment of bipolar disorders

Country Status (19)

Country Link
EP (1) EP0966967A3 (fr)
JP (1) JP2002516864A (fr)
KR (1) KR20010043731A (fr)
CN (1) CN1302207A (fr)
AU (1) AU756468B2 (fr)
BR (1) BR9911068A (fr)
CA (1) CA2332408A1 (fr)
CZ (1) CZ20004280A3 (fr)
EA (1) EA003611B1 (fr)
HR (1) HRP20000798A2 (fr)
HU (1) HUP0102511A2 (fr)
IL (1) IL139591A0 (fr)
NO (1) NO20005884L (fr)
NZ (1) NZ507981A (fr)
PL (1) PL344304A1 (fr)
SK (1) SK17492000A3 (fr)
TR (1) TR200003525T2 (fr)
WO (1) WO1999062522A1 (fr)
ZA (1) ZA200006817B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US6174882B1 (en) * 1998-11-23 2001-01-16 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
FR2802101B1 (fr) * 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
WO2002009694A1 (fr) * 2000-08-02 2002-02-07 Ortho-Mcneil Pharmaceutical, Inc. Derives anticonvulsivants utilises dans le traitement de la depression
AU2002232470B2 (en) * 2001-01-02 2005-11-03 Pharmacia & Upjohn Company Llc New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
EP1404342A1 (fr) * 2001-04-26 2004-04-07 Ortho-Mcneil Pharmaceutical, Inc. Traitement des troubles psychotiques comportant une co-therapie avec des derives anti-convulsions et des anti-psychotiques atypiques
US7973043B2 (en) 2002-07-30 2011-07-05 Peter Migaly Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions
US7410759B2 (en) 2002-11-01 2008-08-12 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosing and treating mood disorders
NZ556779A (en) 2002-12-27 2008-12-24 Otsuka Pharma Co Ltd Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
KR20060009938A (ko) * 2003-05-16 2006-02-01 화이자 프로덕츠 인코포레이티드 양극성 장애 및 연관된 증상의 치료
CN102172401A (zh) * 2003-05-23 2011-09-07 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
EP1713486A4 (fr) 2003-12-02 2009-04-29 Sheldon Leslie James Therapie combinee pour le traitement de la demence, la depression et l'apathie
BRPI0415899A (pt) * 2003-12-15 2007-01-09 Lundbeck & Co As H usos de um composto, e de um antagonista de receptor de h3, agonista inverso ou agonista parcial, composição farmacêutica, método para a identificação de compostos úteis para o tratamento de doenças, e, composto
EP1737473A4 (fr) * 2004-04-19 2009-08-26 Noven Therapeutics Llc Combinaisons de lithium et utilisations associees
US20070264358A1 (en) * 2004-06-04 2007-11-15 Wittlin William A Methods and Compositions for Treating Mood Disorder
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
US8415298B2 (en) 2004-06-21 2013-04-09 The Board Of Trustees Of The Leland Stanford Junior University Of Stanford Administration of FGF2 for treamtent of anxiety
EP1951908B1 (fr) 2005-11-12 2013-08-07 The Board of Trustees of The Leland Stanford Junior University Méthodes associées au fgf2 pour diagnostiquer et traiter une dépression
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
TW200812573A (en) 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
US20080199866A1 (en) * 2006-10-10 2008-08-21 The Board Of Trustees Of The Leland Stanford Junior University Snp detection and other methods for characterizing and treating bipolar disorder and other ailments
GB0814466D0 (en) * 2008-08-07 2008-09-10 Rosemont Pharmaceuticals Ltd Sertraline composition
WO2014078568A1 (fr) 2012-11-14 2014-05-22 The Johns Hopkins University Méthodes et compositions pour le traitement de la schizophrénie
CN108926569A (zh) * 2018-08-24 2018-12-04 山西医科大学第医院 一种非典型抗精神病药物组合物
CN108938645A (zh) * 2018-08-24 2018-12-07 山西医科大学第医院 一种抗精神病药物组合物
CN109464436A (zh) * 2019-01-10 2019-03-15 高智玉 西酞普兰或艾司西酞普兰分别和喹硫平联合在制备治疗精神障碍类疾病的复方制剂中的应用
CN110151718A (zh) * 2019-06-13 2019-08-23 厦门医学院 一种奥氮平口腔崩解片及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000103A1 (fr) * 1990-06-28 1992-01-09 Beecham Group Plc Preparations pharmaceutiques
IL126162A0 (en) * 1996-03-11 1999-05-09 Lilly Co Eli Method for treating bipolar disorder
JP2000507945A (ja) * 1996-03-25 2000-06-27 イーライ・リリー・アンド・カンパニー 痛みを処置する方法
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses

Also Published As

Publication number Publication date
BR9911068A (pt) 2001-02-06
AU756468B2 (en) 2003-01-16
KR20010043731A (ko) 2001-05-25
AU4008899A (en) 1999-12-20
SK17492000A3 (sk) 2002-04-04
PL344304A1 (en) 2001-10-22
NZ507981A (en) 2003-10-31
NO20005884L (no) 2001-01-24
CA2332408A1 (fr) 1999-12-09
EP0966967A3 (fr) 2000-05-31
HRP20000798A2 (en) 2001-10-31
WO1999062522A1 (fr) 1999-12-09
EP0966967A2 (fr) 1999-12-29
HUP0102511A2 (hu) 2001-11-28
EA003611B1 (ru) 2003-06-26
EA200001244A1 (ru) 2001-06-25
CN1302207A (zh) 2001-07-04
JP2002516864A (ja) 2002-06-11
NO20005884D0 (no) 2000-11-21
TR200003525T2 (tr) 2001-04-20
CZ20004280A3 (cs) 2001-09-12
ZA200006817B (en) 2002-02-21

Similar Documents

Publication Publication Date Title
IL139591A0 (en) Combination therapy for treatment of bipolar disorders
EP1063990A4 (fr) Therapie destinee aux troubles lies aux oestrogenes
EP1077704A4 (fr) Therapie combinee destinee au traitement de la depression
HUP0400914A3 (en) Methods of treatment of mitochondrial disorders
HU9803018D0 (en) Methods and compositions for the treatment and prevention of tumors, tumor-veloted disorders and cachexia
IL141263A0 (en) Methods for treatment of neurological disorders
IL139592A0 (en) Combination therapy for treatment of refractory depression
IL136960A0 (en) Combination therapy for the treatment of migraine
IL146131A0 (en) Treatment of neurotic disorders
EP1126850A4 (fr) Traitement des affections de la retine
PL345769A1 (en) Triazolopyridines for the treatment of thrombosis disorders
HUP0102436A3 (en) Use of reboxetin for preparation of medicament for nervous disorders
GB9926968D0 (en) Treatment of neurological disorders
AU7106300A (en) Treatment of skin disorders
IL140540A0 (en) Treatment of anxiety disorders
IL131347A0 (en) Treatment of skin disorders
IL135994A0 (en) Combination therapy for the treatment of aids
IL136025A0 (en) Combination therapy for the treatment of migraine
IL136962A0 (en) Combination therapy for the treatment of migraine
IL136024A0 (en) Combination therapy for the treatment of migraine
GB0020261D0 (en) Therapeutic treatment
HK1040933A1 (zh) N-取代的氮雜二環烷衍生物在治療中樞神經系統疾病中的應用
GC0000176A (en) Pharmaceutical combination preparations for the treatment of cardiac disorders
GB9815188D0 (en) Treatment of skin disorders
GB9819590D0 (en) Combination therapy for the treatment of aids